Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension
暂无分享,去创建一个
Joanna Coast | Heather Draper | Andrew Bottomley | Galina Velikova | Laura Lee Johnson | Melanie Calvert | Doug Altman | Lori Frank | Gary Price | Ethan Basch | Trish Groves | Madeleine T. King | An-Wen Chan | Derek Kyte | Julia Brown | D. Altman | E. Basch | R. Stephens | D. Patrick | A. Bottomley | Jane A. Scott | D. Revicki | R. Golub | M. King | T. Groves | J. Coast | A. Slade | M. Brundage | H. Draper | A. Chan | L. Frank | J. Blazeby | A. Regnault | G. Velikova | M. Palmer | D. Kyte | M. Calvert | Julia M. Brown | S. Mitchell | P. Kluetz | C. Ells | K. Haywood | Michael Brundage | G. Price | Dennis Revicki | Donald Patrick | Rebecca Mercieca-Bebber | Antoine Regnault | L. L. Johnson | Anita Slade | Amanda Hunn | Carolyn Ells | Daniel O’Connor | Jane Blazeby | Jane Scott | Josephine Norquist | Kirstie Haywood | Lisa Campbell | Maria von Hildebrand | Michael Palmer | Paul Kluetz | Richard Stephens | Robert M. Golub | Sandra Mitchell | Derek G Kyte | J. Norquist | R. Mercieca-Bebber | D. O’Connor | Amanda Hunn | Lisa Campbell | M. von Hildebrand
[1] D. Stryer,et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.
[2] Sandra A Mitchell,et al. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[3] Rachel M. Taylor,et al. Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol , 2016, BMJ Open.
[4] H. Draper,et al. Patient-reported outcome alerts: ethical and logistical considerations in clinical trials. , 2013, Journal of the American Medical Association (JAMA).
[5] Caroline B. Terwee,et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline , 2016, Trials.
[6] Lori Frank,et al. The PCORI perspective on patient-centered outcomes research. , 2014, JAMA.
[7] D. G. Altman,et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research , 2017, Research Involvement and Engagement.
[8] Inconsistencies in Quality of Life Data Collection in Clinical Trials: A Potential Source of Bias? Interviews with Research Nurses and Trialists , 2013, PloS one.
[9] H. Draper,et al. Current practices in patient-reported outcome (PRO) data collection in clinical trials: a cross-sectional survey of UK trial staff and management , 2016, BMJ Open.
[10] M. Stockler,et al. The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training , 2017, Contemporary clinical trials communications.
[11] M. King,et al. Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers , 2014, PloS one.
[12] L. Collette,et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. , 2016, The Lancet. Oncology.
[13] P. Fayers,et al. Quality of life assessment in clinical trials—guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience , 1997 .
[14] D. Wild,et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] David Cella,et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] D. Osoba,et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. , 1998, Statistics in medicine.
[17] H. Draper,et al. Management of Patient-Reported Outcome (PRO) Alerts in Clinical Trials: A Cross Sectional Survey. , 2016, PloS one.
[18] R. Hays,et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. , 2008, Journal of clinical epidemiology.
[19] M. Stockler,et al. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols , 2016, Quality of Life Research.
[20] D. Moher,et al. Putting patients at the heart of health-care research , 2015, The Lancet.
[21] D. Cella,et al. Developing a Valid Patient‐Reported Outcome Measure , 2011, Clinical pharmacology and therapeutics.
[22] D A Revicki,et al. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] S. Staniszewska,et al. Establishing the values for patient engagement (PE) in health-related quality of life (HRQoL) research: an international, multiple-stakeholder perspective , 2016, Quality of Life Research.
[24] D. Patrick. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] Melanie Calvert,et al. Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review , 2016, BMJ Open.
[26] Matthias Briel,et al. Evaluation of the patient-reported outcome (PRO) content of clinical trial protocols , 2014 .
[27] A. Gnanasakthy,et al. Patient reported outcomes: looking beyond the label claim , 2010, Health and quality of life outcomes.
[28] M. King. A point of minimal important difference (MID): a critique of terminology and methods , 2011, Expert review of pharmacoeconomics & outcomes research.
[29] Jane M Blazeby,et al. Developing core outcome sets for clinical trials: issues to consider , 2012, Trials.
[30] D. Moher,et al. Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.
[31] David Moher,et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.
[32] D. Fairclough. Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.
[33] N. Santanello,et al. Analysis and interpretation of results based on patient-reported outcomes. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] M. King,et al. Mode of administration does not cause bias in patient-reported outcome results: a meta-analysis , 2016, Quality of Life Research.
[35] U. Gunnarsson,et al. Quality of life in patients with a permanent stoma after rectal cancer surgery , 2016, Quality of Life Research.
[36] David Moher,et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. , 2015, Revista panamericana de salud publica = Pan American journal of public health.